That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
GSK has agreed to pay $58 per RAPT share, with an upfront payment of $1.9 billion, that will give it global rights to ...
US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults ...
Investor's Business Daily on MSN
GSK digs in on allergies with $2.2 billion Rapt Therapeutics buyout
GSK is buying Rapt Therapeutics for $2.2 billion, the companies said Tuesday. Rapt stock rocketed.
The growing scourge of food allergies drove U.K. heavyweight pharmaceutical GSK to announce a $2.2 billion deal on Tuesday.
GSK plc agreed to buy Rapt Therapeutics, a US-based biotech developing treatments for patients with inflammatory and ...
The Daily Overview on MSNOpinion
GSK grabs RAPT for $2.2B in big bet on food allergy drugs
GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results